Skip to main content

Table 3 Summary of clinical interventions/adverse events in terms of re-intubation and tachycardia among dosing regimens

From: Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates

Dosing regimens Number of patients going through re-intubation (%) Number of patients having tachycardia (%)
Secondary to apnea of prematurity Secondary to other respiratory etiologies
40/5 mg/kg
 q12h 4 (8.5 %) 7 (14.9 %) 21*** (44.7 %)
20/5 mg/kg
 q24h 4 (8.2 %) 8 (16.3 %) 5 (10.2 %)
 q12h 0 1 (12.5 %) 4 (50.0 %)
5/5 mg/kg
 q24h 2 (33.3 %) 0 1 (16.7 %)
 q12h 0 1 (20.0 %) 0
  1. *** p < 0.001, regimen 40/5 mg/kg q12h led to significantly higher percentage of patients experiencing tachycardia secondary to caffeine citrate therapy than standard 20/5 mg/kg q24h